IN THE NAME OF GOD By: Dr malek. References Am J Clin Pathol. 2008;130(5):688- 695. © 2008 American Society for Clinical Pathology Bryant J, Picot J,

Slides:

Advertisements

Similar presentations

AST in AMI CK in AMI electrophoresis for CK and LD isoenzymes INH for CK-MB RIA for myoglobin WHO criteria for AMI CK-MB mass.

Advertisements

1 Title 1 Subtitle 2 Chemotherapy Induced Cardiac Toxicity Russell Huntsinger, MD Cardiologist.

CD10, scored as positive versus negative all path 1 path 2 path 3 path 4 path 5 path 6 path 7 path 8 path 9 CD10 can be reproducibly scored, but is very.

Early assessment of myocardial injury by joint measurement of TnT-hs and Copeptin (1) J. Teixeira, (2) P. Wotquenne, (2) V. D’Orio, (3) D. Gruson, (1)

CARDIOVASCULAR EFFECTS OF ANTHRACYCLINE-LIKE CHEMOTHERAPY AGENTS JOHN N. HAMATY FACC, FACOI.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

British Association of Urological Surgeons Metastatic Prostate Cancer Guidelines.

Abstract: Vigilant Cardiac Function Monitoring in Childhood Cancer Survivors: A Specialized Team Approach Emily Mueller, MD 1, Linda Rivard, RN 2,3, Marc.

Comparison of Echocardiographic Methods to Cardiac Magnetic Resonance Imaging in Survivors of Pediatric Cancer Jeet Mehta 1, Sanket Shah 1,2 Wendy McClellan.

High Sensitivity Troponin

CRITICAL READING OF THE LITERATURE RELEVANT POINTS: - End points (including the one used for sample size) - Surrogate end points - Quality of the performed.

Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) 1 Concordance of HER2 Central Assessment.

1Statistics 741, Chappell - Spring 2012 Rick Chappell, Ph.D. Professor, Department of Biostatistics and Medical Informatics Department of Statistics University.

Cardiac Markers byN.X.. Cardiac Markers 1. After the loss of integrity of cardiac myocyte membranes, intracellular macromolecules diffuse into the interstitium.

A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)

Duchenne Muscular Dystrophy: Cardiac Management. Introduction Aim: early detection and treatment of deterioration in heart muscle function Cardiac disease.

How can new diagnostic methods contribute in healthcare? What are doctors looking for? Better support in their clinical decision makings, which includes:

Utility of Post-Therapy Surveillance Scans in Diffuse Large B-Cell Lymphoma Thompson C et al. Proc ASCO 2013;Abstract 8504.

Biochemical Markers of Myocardial Infarction

Prognostic Utility of Secretory Phospholipase A 2 in Patients with Stable Coronary Artery Disease M. O'Donoghue, Z. Mallat, D.A. Morrow, J. Benessiano,

UOG Journal Club: January 2013

A view of Novel Cardiac Biomarkers in Heart Failure.

Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,

Anthracycline induced Cardiomyopathy AM Report December AM Report December

Marius M Hoeper Therapeutic goals and algorithms.

1 ASSESSMENT OF LEFT VENTRICULAR SYSTOLIC DYSFUNCTION BY TISSUE DOPPLER IMAGING SHOWS EVIDENCE OF SUBCLINICAL CARDIOMYOPATHY EARLY AFTER ATHRACYCLINE THERAPY.

Biochemical Markers for Diagnosis of Myocardial Infarction Cardiovascular Block Medical Biochemistry Course Dr. Reem M. Sallam, MD, PhD.

Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the.

7th Global Summit October 05-07, 2015 on Cancer Therapy Dubai, UAE CD49d and CD26 are independent prognostic markers for disease progression in patients.

Use of Oncotype Dx® Testing Breast SSG meeting 10 th July 2015 Dr Rebecca Bowen.

Ischaemic Heart Disease CASE A. CASE A: Mr HA, aged 60 years, was brought in to A&E complaining of chest pain, nausea and a suspected AMI.

Corinne Haioun et al. Survival benefit of high dose therapy in poor risk aggressive non Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protcol-

Journal Club Optimizing Early Rule-Out Strategies for Acute Myocardial Infarction: Utility of 1-Hour Copeptin P. Hillinger, R. Twerenbold, C. Jaeger, K.

Introduction BACKGROUND  N on-sustained VT (NSVT) is a known risk factor for poor outcomes in adults with HCM and diastolic dysfunction is linked to poor.

The percentage of values for cardiac troponin (cTn)T associated with elevated values for a point-of-care assay with less sensitivity and precision: the.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

RESEARCH POSTER PRESENTATION DESIGN © Cardiac Troponin Assay Cardiac troponin I is the diagnostic marker used for myocardial.

Risk Involved with Dual RAAS Blockade in Kidney Disease Source: Bakris GL. Dual RAAS blockade is desirable in kidney disease: Con. Kidney Int. 2010;78:546–549.

University of Auckland Nursing 785 Assignment 3. Marc McLaughlin

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

Conclusions Results Methods Background Venous thrombo-embolism in patients undergoing neo- adjuvant chemotherapy and surgery for oesophago-gastric cancer.

PHARE Trial Results of Subset Analysis Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer Pivot X et al. Proc SABCS 2012;Abstract.

Depart. of Pulmonology 백승숙. More than 80% of cases of tuberculosis in the United States –The result of reactivated latent infection –Nearly all these.

PROSPECTIVE CYTOMEGALOVIRUS (CMV) MONITORING IN ACUTE MYELOID LEUKAEMIA DURING FIRST LINE THERAPY Capria S, Gentile G, Trisolini SM, Capobianchi A, Cardarelli.

Cardiotoxicity associated with the cancer therapeutic agent sunitinib Telli ML, Witteles RM, Fisher GA, Srinivas S. Reviewed by:

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: N-terminal pro brain natriuretic peptide on admission.

Estimated Glomerular Filtration Rate and Albuminuria Are Associated with Biomarkers of Cardiac Injury in a Population-Based Cohort Study: The Maastricht.

Slamon D et al. SABCS 2009;Abstract 62.

UAB medical Center, Birmingham VA Medical Center

Conflicts of interest Major role in development of GRADE

Cardiac enzymes. 2 – Non enzyme proteins The Troponins

Screening and diagnosis of AF and stratifying stroke risk

Introduction to Clinical Pharmacy

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Information for participating Sites

Maya Guglin, MD, PhD University of Kentucky, Lexington, KY

Cardiac Troponin.

Joerg Herrmann, MD, Amir Lerman, MD, Nicole P

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

G. Michael Felker et al. JCHF 2014;2:

Section III: Neurohormonal strategies in heart failure

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Biochemical Markers of Myocardial Infarction

Figure 1 Novel markers of increased stroke risk in AF

Analysis of receiver operating characteristic of three models (model 1: cardiac troponin T (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP),

Presentation transcript:

IN THE NAME OF GOD By: Dr malek

References Am J Clin Pathol. 2008;130(5): © 2008 American Society for Clinical Pathology Bryant J, Picot J, Baxter L, et al. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer. 2007;43:

cardiac monitoring At least 3 international consensus guidelines recommend evaluation of LVEF at the beginning of antineoplastic therapy, after administration of half the total anthracycline cumulative dose, and before every subsequent dose. Moreover, during follow-up, LVEF evaluation 3, 6, and 12 months after the end of treatment is recommended A decline of LVEF by more than 10%, associated with an absolute LVEF value of less than 50%, is suggested as a criterion for suspending treatment

cardiac monitoring Children receiving anthracycline therapy should have their cardiac function closely monitored during treatment. Echocardiograms or radionuclide cineangiography are generally recommended before starting therapy and then periodically before courses of anthracyclines

Biochemical Markers for Prediction of Chemotherapy-Induced Cardiotoxicity the clinical application of cardiac troponin as a cardiotoxicity biomarker was analyzed in 7 studies with a consistent number of subjects (>40 patients enrolled) monitored by troponin I (cTnI) and T (cTnT), for a total number of almost 1,500 patients with cancer

Biochemical Markers for Prediction of Chemotherapy-Induced Cardiotoxicity Adopting a univocal definition of positivity makes the troponin test very useful in clinical practice to monitor patients independent of the method used and of the laboratory performing the assay.

Biochemical Markers for Prediction of Chemotherapy-Induced Cardiotoxicity Troponin peak value was observed at different intervals after high-dose chemotherapy, so that several samples were required to detect it. Furthermore, the time point at which a negative troponin value reached 100% of specificity for no further troponin releases cannot be defined

Biochemical Markers for Prediction of Chemotherapy-Induced Cardiotoxicity In clinical practice, an interesting perspective that requires further scientific evidence is the ability of troponin to identify subclinical stages of cardiotoxicity, allowing for specific cardioprotective therapies aimed at slowing or blocking the evolution of left ventricular dysfunction due to cardiotoxicity

In lieu of definitive evidence, it is not currently possible to recommend the use of the CNP assay to assess cardiotoxicity in clinical practice, even if some results may suggest this possibility. New prospective studies, including large cohorts of patients, using well-validated and commercially available methods that compare BNP/NT-proBNP assays with well- established markers of cardiotoxicity

such as cardiac troponins, are needed. Furthermore, in a recent systematic review that evaluated the effectiveness of different cardiac markers, mainly natriuretic peptides, to assess anthracycline-induced cardiotoxicity in children with cancer, results showed limited evidence, making conclusions problematic.

Conclusions Cardiotoxicity has a strong impact on patients with cancer, in clinical and prognostic terms. Early detection is crucial for applying preventive and supportive therapeutic strategies. The role of cardiac troponin determination to stratify the cardiotoxicity risk is currently based on strong evidence clearly suggesting the routine use of this biomarker.